Found 120 clinical trials
Comparation of Chidamide Plus VRD (Bortezomib Lenalidomide Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that of VRD regimen.
- 2 views
- 23 Jan, 2021
- 1 location
Daratumumab Combined With Bortezomib Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease
This trial will try to establish the feasibility and efficacy of the combination of DaraVCD in Multiple Myeloma (MM) patients presenting with extramedullary disease (EMD). The study will be conducted as a Phase II trial. Forty patients will be included in the study cohort. All patients will be followed closely …
- 3 views
- 10 Feb, 2021
- 8 locations
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
and bortezomib in adults with relapsed/refractory multiple myeloma (MM).
- 0 views
- 18 Jul, 2021
- 7 locations
Carfilzomib Lenalidomide and Dexamethasone Versus Bortezomib Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.
- 71 views
- 14 Jun, 2021
- 1 location
Daratumumab Bortezomib and Dexamethasone Followed by Daratumumab Ixazomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well daratumumab, bortezomib, and dexamethasone followed by daratumumab, ixazomib, and dexamethasone in treating patients with multiple myeloma that has come back
- 3 views
- 18 Apr, 2021
- 1 location
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide Bortezomib and Dexamethasone (CyBorD) for NDMM NTE
This is a phase 2A multi-centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed
- 0 views
- 31 Jul, 2021
- 4 locations
Study of Isatuximab+Lenalidomide+Dexamethasone With/Without Bortezomib in de Novo Non Frail NTE Multiple Myeloma Elderly Patients
induction regimens to lenalidomide-based associations, which is now the backbone of most treatment for NTE patients. Even though the latest melphalan, bortezomib and prednisone (MPV) association was
- 0 views
- 11 Nov, 2021
- 1 location
Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma
This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in
- 2 views
- 18 Nov, 2021
- 1 location
DARA RVD For High Risk SMM
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating
- 0 views
- 30 Oct, 2021
- 2 locations
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib is a drug that
- 5 views
- 20 Jun, 2021
- 1 location